Trial Profile

A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE study) )

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostemsavir (Primary)
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms BRIGHTE
Sponsors Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; ViiV Healthcare

01 Mar 2025 Results (n=16) assessing how evolving antibody responses in the presence of drug correlate with delayed viral suppression published in the Antiviral Research
29 Jan 2025 Planned End Date changed from 31 Dec 2026 to 31 Dec 2025.
23 Jul 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com